Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives

Natarajan V. Bhanu, Y. Terry Lee, Patricia A. Oneal, Nicole M. Gantt, Wulin Aerbajinai, Pierre Noel, Craig J. Thomas, Jeffery L. Miller

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In vivo, inhibition of fetal hemoglobin (HbF) expression in humans around the time of birth causes the clinical manifestation of sickle cell and beta-thalassemia syndromes. Inhibition of HbF among cultured cells was recently described by the adenosine derivative molecule named SQ22536. Here, a primary cell culture model was utilized to further explore the inhibition of HbF by adenosine derivative molecules. SQ22536 demonstrated down-regulation of growth and HbF expression among erythroblasts cultured from fetal and adult human blood. The effects upon HbF were noted in a majority of cells, and quantitative PCR analysis demonstrated a transcriptional mechanism. Screening assays demonstrated that two additional molecules named 5′-deoxy adenosine and 2′,3′-dideoxy adenosine had effects on HbF comparable to SQ22536. Other adenosine derivative molecules, adenosine receptor binding ligands, and cAMP-signaling regulators failed to inhibit HbF in matched cultures. These results suggest that structurally related ribofuranose-substituted adenosine analogues act through an unknown mechanism to inhibit HbF expression in fetal and adult human erythroblasts.

Original languageEnglish (US)
Pages (from-to)504-510
Number of pages7
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1782
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Erythroblasts
Adenosine
Growth
Purinergic P1 Receptors
Primary Cell Culture
beta-Thalassemia
Cultured Cells
Down-Regulation
Parturition
Ligands
Polymerase Chain Reaction

Keywords

  • Adenosine derivative
  • Cytokine
  • HbF inhibition
  • Hemoglobinopathy
  • Human erythropoiesis
  • SQ22536

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives. / Bhanu, Natarajan V.; Lee, Y. Terry; Oneal, Patricia A.; Gantt, Nicole M.; Aerbajinai, Wulin; Noel, Pierre; Thomas, Craig J.; Miller, Jeffery L.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1782, No. 9, 09.2008, p. 504-510.

Research output: Contribution to journalArticle

Bhanu, Natarajan V. ; Lee, Y. Terry ; Oneal, Patricia A. ; Gantt, Nicole M. ; Aerbajinai, Wulin ; Noel, Pierre ; Thomas, Craig J. ; Miller, Jeffery L. / Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2008 ; Vol. 1782, No. 9. pp. 504-510.
@article{77433455563e47f89db20046a2419286,
title = "Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives",
abstract = "In vivo, inhibition of fetal hemoglobin (HbF) expression in humans around the time of birth causes the clinical manifestation of sickle cell and beta-thalassemia syndromes. Inhibition of HbF among cultured cells was recently described by the adenosine derivative molecule named SQ22536. Here, a primary cell culture model was utilized to further explore the inhibition of HbF by adenosine derivative molecules. SQ22536 demonstrated down-regulation of growth and HbF expression among erythroblasts cultured from fetal and adult human blood. The effects upon HbF were noted in a majority of cells, and quantitative PCR analysis demonstrated a transcriptional mechanism. Screening assays demonstrated that two additional molecules named 5′-deoxy adenosine and 2′,3′-dideoxy adenosine had effects on HbF comparable to SQ22536. Other adenosine derivative molecules, adenosine receptor binding ligands, and cAMP-signaling regulators failed to inhibit HbF in matched cultures. These results suggest that structurally related ribofuranose-substituted adenosine analogues act through an unknown mechanism to inhibit HbF expression in fetal and adult human erythroblasts.",
keywords = "Adenosine derivative, Cytokine, HbF inhibition, Hemoglobinopathy, Human erythropoiesis, SQ22536",
author = "Bhanu, {Natarajan V.} and Lee, {Y. Terry} and Oneal, {Patricia A.} and Gantt, {Nicole M.} and Wulin Aerbajinai and Pierre Noel and Thomas, {Craig J.} and Miller, {Jeffery L.}",
year = "2008",
month = "9",
doi = "10.1016/j.bbadis.2008.05.004",
language = "English (US)",
volume = "1782",
pages = "504--510",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives

AU - Bhanu, Natarajan V.

AU - Lee, Y. Terry

AU - Oneal, Patricia A.

AU - Gantt, Nicole M.

AU - Aerbajinai, Wulin

AU - Noel, Pierre

AU - Thomas, Craig J.

AU - Miller, Jeffery L.

PY - 2008/9

Y1 - 2008/9

N2 - In vivo, inhibition of fetal hemoglobin (HbF) expression in humans around the time of birth causes the clinical manifestation of sickle cell and beta-thalassemia syndromes. Inhibition of HbF among cultured cells was recently described by the adenosine derivative molecule named SQ22536. Here, a primary cell culture model was utilized to further explore the inhibition of HbF by adenosine derivative molecules. SQ22536 demonstrated down-regulation of growth and HbF expression among erythroblasts cultured from fetal and adult human blood. The effects upon HbF were noted in a majority of cells, and quantitative PCR analysis demonstrated a transcriptional mechanism. Screening assays demonstrated that two additional molecules named 5′-deoxy adenosine and 2′,3′-dideoxy adenosine had effects on HbF comparable to SQ22536. Other adenosine derivative molecules, adenosine receptor binding ligands, and cAMP-signaling regulators failed to inhibit HbF in matched cultures. These results suggest that structurally related ribofuranose-substituted adenosine analogues act through an unknown mechanism to inhibit HbF expression in fetal and adult human erythroblasts.

AB - In vivo, inhibition of fetal hemoglobin (HbF) expression in humans around the time of birth causes the clinical manifestation of sickle cell and beta-thalassemia syndromes. Inhibition of HbF among cultured cells was recently described by the adenosine derivative molecule named SQ22536. Here, a primary cell culture model was utilized to further explore the inhibition of HbF by adenosine derivative molecules. SQ22536 demonstrated down-regulation of growth and HbF expression among erythroblasts cultured from fetal and adult human blood. The effects upon HbF were noted in a majority of cells, and quantitative PCR analysis demonstrated a transcriptional mechanism. Screening assays demonstrated that two additional molecules named 5′-deoxy adenosine and 2′,3′-dideoxy adenosine had effects on HbF comparable to SQ22536. Other adenosine derivative molecules, adenosine receptor binding ligands, and cAMP-signaling regulators failed to inhibit HbF in matched cultures. These results suggest that structurally related ribofuranose-substituted adenosine analogues act through an unknown mechanism to inhibit HbF expression in fetal and adult human erythroblasts.

KW - Adenosine derivative

KW - Cytokine

KW - HbF inhibition

KW - Hemoglobinopathy

KW - Human erythropoiesis

KW - SQ22536

UR - http://www.scopus.com/inward/record.url?scp=49349088682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49349088682&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2008.05.004

DO - 10.1016/j.bbadis.2008.05.004

M3 - Article

C2 - 18586086

AN - SCOPUS:49349088682

VL - 1782

SP - 504

EP - 510

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 9

ER -